Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues
Meghali Goswami(National Institutes of Health), Christopher S. Hourigan(National Heart Lung and Blood Institute), Trivikram Rajkhowa(Dana-Farber Cancer Institute), Sawa Ito(National Institutes of Health), Stephen A. Strickland(Vanderbilt University), Hossein Sadrzadeh(Boston University), Natasha A. Jain(National Institutes of Health), Gabrielle T. Prince(Johns Hopkins University), Madan Jagasia(Vanderbilt University Medical Center), Minoo Battiwalla(Sarah Cannon), James W. Fraser(Harvard University), Bipin N. Savani(Vanderbilt University Medical Center), Mark J. Levis(Sidney Kimmel Cancer Center), Qin Lu(Soochow University), Hyam I. Levitsky(Century Therapeutics (United States)), Nancy F. Hensel(National Heart Lung and Blood Institute), Amir T. Fathi(University of Southern California), A. John Barrett(National Heart Lung and Blood Institute), B. Douglas Smith(Johns Hopkins University)
Cited by 34
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k